Occudo Quantitative Strategies LP Takes $207,000 Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Occudo Quantitative Strategies LP bought a new position in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 10,567 shares of the company's stock, valued at approximately $207,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Deutsche Bank AG raised its stake in shares of Privia Health Group by 11.7% during the fourth quarter. Deutsche Bank AG now owns 272,973 shares of the company's stock valued at $5,337,000 after acquiring an additional 28,556 shares during the last quarter. Durable Capital Partners LP increased its holdings in Privia Health Group by 3.4% in the fourth quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company's stock valued at $224,587,000 after purchasing an additional 378,255 shares during the period. Bank of America Corp DE raised its position in Privia Health Group by 5.1% during the 4th quarter. Bank of America Corp DE now owns 1,021,763 shares of the company's stock worth $19,975,000 after purchasing an additional 49,389 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Privia Health Group during the 4th quarter worth about $4,321,000. Finally, Algert Global LLC lifted its holdings in Privia Health Group by 639.1% during the 4th quarter. Algert Global LLC now owns 108,048 shares of the company's stock worth $2,112,000 after buying an additional 93,429 shares during the period. 94.48% of the stock is owned by institutional investors.

Insider Transactions at Privia Health Group

In related news, Director Matthew Shawn Morris sold 10,309 shares of Privia Health Group stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $240,508.97. Following the completion of the sale, the director now owns 59,792 shares of the company's stock, valued at approximately $1,394,947.36. This trade represents a 14.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Parth Mehrotra sold 15,100 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $352,283.00. Following the transaction, the chief executive officer now owns 454,281 shares in the company, valued at approximately $10,598,375.73. The trade was a 3.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 51,579 shares of company stock valued at $1,226,367 in the last 90 days. 10.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Robert W. Baird raised their price objective on Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 15th. Barclays increased their target price on shares of Privia Health Group from $21.00 to $23.00 and gave the company an "equal weight" rating in a research report on Thursday, April 10th. Canaccord Genuity Group raised their price target on shares of Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, February 28th. JMP Securities reaffirmed a "market outperform" rating and issued a $29.00 price objective on shares of Privia Health Group in a research note on Monday, April 28th. Finally, Truist Financial lifted their target price on shares of Privia Health Group from $27.00 to $28.00 and gave the stock a "buy" rating in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $27.38.

Privia Health Group Stock Down 2.9%

NASDAQ:PRVA traded down $0.72 during trading hours on Wednesday, reaching $23.80. The company had a trading volume of 474,138 shares, compared to its average volume of 751,644. Privia Health Group, Inc. has a twelve month low of $15.92 and a twelve month high of $26.09. The firm has a market cap of $2.90 billion, a price-to-earnings ratio of 238.02, a P/E/G ratio of 3.47 and a beta of 0.87. The business's 50-day simple moving average is $23.40 and its two-hundred day simple moving average is $22.63.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.